Скачать с ютуб Rheumatoid Arthritis and the Potential of Exploring Combination Therapies в хорошем качестве

Rheumatoid Arthritis and the Potential of Exploring Combination Therapies

Dr. Terence Rooney, Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shares new data that was presented from the Phase 2a IRIS proof-of-concept study, demonstrating the efficacy and safety of nipocalimab in the first-ever clinical study of an FcRn inhibitor in adults living with moderate to severe rheumatoid arthritis, and supporting its progression into an anti-TNF combination study. These data were presented at the 2023 American College of Rheumatology (ACR) Convergence. #ACR23 #Immunology #Rheumatology Terence Rooney, M.D., is Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology disease area, overseeing innovative compounds across multiple phases of development. In his prior role at Janssen as Vice President, Immunology Clinical Development, Terence led the Late Development Clinical organization, overseeing all late-stage Immunology clinical trials. Under his leadership, the team delivered many important milestones, and evolved to meet the present and future needs of our growing and complex Immunology portfolio more sustainably. Prior to his time at Janssen, Terence held positions of increasing responsibility in translational/early and late clinical development at Roche and Eli Lilly, respectively. Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development. Terence is based at the Spring House, Pennsylvania campus, and lives with his family in Gladwyne, Pennsylvania. Follow Terence on LinkedIn here.